The National Cancer Center Japan (NCC) has announced the start of a new clinical trial for an anticancer drug prescreened with tumor-bearing mice, saying the use of such mouse models could significantly accelerate the nation’s drug development.
The NCC has a collection of patient-derived xenograft (PDX) mouse models called J-PDX, which are immunodeficient mice that have had the live tumor tissues of patients transplanted onto their backs.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.